Lamichhane, N., Melas, N., Bergqvist, V., Ekholm, N.-P., Olén, O., Ludvigsson, J. F., Hjortswang, H., Marsal, J., Eriksson, C., & Halfvarson, J. (2024). Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 69(6), 2175–2183. https://doi.org/10.1007/s10620-024-08422-9

Travis, S., Silverberg, M. S., Danese, S., Gionchetti, P., Löwenberg, M., Jairath, V., Feagan, B. G., Bressler, B., Ferrante, M., Hart, A., Lindner, D., Escher, A., Jones, S., & Shen, B. (2023). Vedolizumab for the Treatment of Chronic Pouchitis. New England Journal of Medicine, 388(13), 1191–1200. https://doi.org/10.1056/nejmoa2208450

Shen, B., Kochhar, G. S., Rubin, D. T., Kane, S. V., Navaneethan, U., Bernstein, C. N., Cross, R. K., Sugita, A., Schairer, J., Kiran, R. P., Fleshner, P., McCormick, J. T., D’Hoore, A., Shah, S. A., Farraye, F. A., Kariv, R., Liu, X., Rosh, J., Chang, S., … Pardi, D. S. (2022). Treatment of pouchitis, Crohn’s disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology & Hepatology, 7(1), 69–95. https://doi.org/10.1016/s2468-1253(21)00214-4